ICO Share Price Performance
SEK 0
-1.18 (-100.00%)
Price SEK 0
Share Pricen/a
Iconovo AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ICO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Iconovo AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 20, 2026
- -0.42
- 70.72%
- -291.31%
- 0%
About ICO
- Founded
- 2013
- Employees
- 12
- CEO
- WebsiteView website
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.
